Sandoz Private Limited — Mycophenolate Exporter Profile
Indian Pharmaceutical Exporter · #4 for Mycophenolate · $10.2M export value · DGFT Verified
Sandoz Private Limited is the #4 Indian exporter of Mycophenolate with $10.2M in export value and 204 verified shipments. Sandoz Private Limited holds a 3.0% market share in Mycophenolate exports across 8 countries. The company exports 25 pharmaceutical products worth $159.4M across 15 therapeutic categories.
Sandoz Private Limited — Mycophenolate Export Profile: Buyers & Destinations
Where Does Sandoz Private Limited Export Mycophenolate?
| Country | Value | Shipments | Share |
|---|---|---|---|
| UNITED STATES | $6.0M | 120 | 62.5% |
| AUSTRALIA | $1.2M | 26 | 13.1% |
| CANADA | $1.2M | 27 | 12.3% |
| PANAMA | $1.0M | 22 | 10.9% |
| PARAGUAY | $97.3K | 3 | 1.0% |
| BANGLADESH | $21.6K | 1 | 0.2% |
| SLOVENIA | $330 | 2 | 0.0% |
| MEXICO | $204 | 3 | 0.0% |
Sandoz Private Limited exports Mycophenolate to 8 countries. The largest destination is UNITED STATES accounting for 62.5% of Sandoz Private Limited's Mycophenolate shipments, followed by AUSTRALIA (13.1%) and CANADA (12.3%). These destinations reflect Sandoz Private Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Mycophenolate from Sandoz Private Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| SANDOZ INC. C/O EXEL, INC. | UNITED STATES | $3.6M | 72 |
| SANDOZ INC C O EXEL INC | UNITED STATES | $1.9M | 38 |
| SANDOZ CANADA INC. C/O UPS SCS | CANADA | $738.6K | 17 |
| SANDOZ PTY LTD | AUSTRALIA | $722.6K | 15 |
| TEVA PHARMACEUTICALS USA INC | UNITED STATES | $350.0K | 7 |
| SANDOZ PTY LTD. | AUSTRALIA | $287.8K | 6 |
| NOVARTIS PHARMA (LOGISTICS), INC | PANAMA | $250.0K | 5 |
| SANDOZ PTY LIMITED | AUSTRALIA | $239.5K | 5 |
| SANDOZ CANADA INC C O UPS SCS | CANADA | $238.2K | 6 |
| SANDOZ CANADA INC | CANADA | $200.0K | 4 |
Sandoz Private Limited supplies Mycophenolate to 24 buyers globally. The largest buyer is SANDOZ INC. C/O EXEL, INC. (UNITED STATES), followed by SANDOZ INC C O EXEL INC (UNITED STATES) and SANDOZ CANADA INC. C/O UPS SCS (CANADA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Mycophenolate Export Value and How Much Does Sandoz Private Limited Contribute?
India exported $86.9M worth of Mycophenolate through 2,529 shipments from 167 suppliers to 100 countries, serving 512 buyers globally. Sandoz Private Limited contributes $10.2M to this total, accounting for 3.0% of India's Mycophenolate exports. Sandoz Private Limited ships Mycophenolate to 8 countries through 24 buyers.
What Is the Average Shipment Value for Sandoz Private Limited's Mycophenolate Exports?
Sandoz Private Limited's average Mycophenolate shipment value is $50.0K per consignment, based on 204 shipments totaling $10.2M. The largest destination is UNITED STATES (62.5% of Sandoz Private Limited's Mycophenolate exports).
How Does Sandoz Private Limited Compare to Other Indian Mycophenolate Exporters?
Sandoz Private Limited ranks #4 among 167 Indian Mycophenolate exporters with a 3.0% market share. The top 3 exporters are INTAS PHARMACEUTICALS LIMITED ($22.7M), ALKEM LABORATORIES LIMITED ($17.8M), EMCURE PHARMACEUTICALS LIMITED ($14.0M). Sandoz Private Limited processed 204 shipments to 8 destination countries.
What Mycophenolate Formulations Does Sandoz Private Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| MYCOPHENOLATE MOF 500MG 100FCT BO US MAT | $1.7M | 34 |
| MYCOPHENOLATE MOF 250MG 100HGC BO US MATERIAL NO. - 44014696 | $399.5K | 8 |
| MYCOPHENOLATE SDZ 500MG 50FCT AU MATERIA | $300.0K | 6 |
| MYCOPHENOLATE MOF 250MG 100HGC BO US MAT | $300.0K | 6 |
| MYCOPHENOLATE MOF 250MG 500HGC BO US MAT | $250.0K | 5 |
| MYCOPHENOLATE 250MG 50HGC V1 CA MATERIAL | $250.0K | 5 |
| MYCOPHENOLATE MOF 500MG 100FCT BO US MATERIAL NO. - 44014700 | $250.0K | 5 |
| MATERIAL NO. 44014700 MYCOPHENOLATE MOF 500MG 100FCT BO US | $250.0K | 5 |
| MYCOPHENOLATE 250MG 50HGC V1 CA MATERIALNO. - 44096937PCS | $201.7K | 6 |
| MYCOPHENOLATE SDZ 250MG 100HGC AU MATERI | $200.0K | 4 |
Sandoz Private Limited exports 85 distinct Mycophenolate formulations including tablets, capsules, syrups, and combination drugs. The top formulation is MYCOPHENOLATE MOF 500MG 100FCT BO US MAT with 34 shipments worth $1.7M.
Regulatory Requirements: Exporting Mycophenolate to Key Markets
What Sandoz Private Limited must comply with to export Mycophenolate to its top destination countries
United States — FDA
Approval Process
ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.
Timeline: 10–18 months for ANDA approval
GMP & Export Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA
Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system
Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.
Australia — TGA
Approval Process
Registration on Australian Register of Therapeutic Goods (ARTG). Bioequivalence and quality data per TGA guidelines.
Timeline: 10–14 months
GMP & Export Requirements
TGA GMP clearance; PIC/S-aligned inspection. PIC/S certificate from India may expedite.
TGA sponsor licence for Australian importer; GMP clearance per manufacturing site
Note: TGA participates in PIC/S mutual recognition.
Canada — HC
Approval Process
ANDS (Abbreviated New Drug Submission) referencing Canadian Reference Product. Comparative bioavailability study required.
Timeline: 12–18 months
GMP & Export Requirements
Health Canada GMP (GUI-0001); Drug Establishment Licence (DEL) inspection
Drug Identification Number (DIN) for each product; Certificate of Pharmaceutical Product from CDSCO
Note: Subject to Good Import Practices and annual C.01.014.6 review.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Sandoz Private Limited Compare to Nearest Mycophenolate Exporters?
Exporters ranked immediately above and below #4 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 3 | ALKEM LABORATORIES LIMITED | $17.8M | 356 | 9 | $50.0K |
| 5 | EMCURE PHARMACEUTICALS LIMITED | $14.0M | 299 | 23 | $46.7K |
| 4 | SANDOZ PRIVATE LIMITED ★ | $10.2M | 204 | 8 | $50.0K |
| 2 | STRIDES PHARMA SCIENCE LIMITED | $9.7M | 193 | 3 | $50.0K |
| 6 | CONCORD BIOTECH LIMITED | $6.0M | 119 | 8 | $50.0K |
Sandoz Private Limited ranks #4 among 167 Indian Mycophenolate exporters. Average shipment value of $50.0K compared to the market average of $520.1K. The closest competitors by value are ALKEM LABORATORIES LIMITED and EMCURE PHARMACEUTICALS LIMITED.
Which Indian Ports Ship Mycophenolate Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 464 | 18.3% |
| NHAVA SHEVA SEA (INNSA1) | 308 | 12.2% |
| SAHAR AIR CARGO ACC (INBOM4) | 229 | 9.1% |
| JNPT/ NHAVA SHEVA SEA | 135 | 5.3% |
| DELHI AIR | 115 | 4.5% |
| AHEMDABAD AIR ACC (INAMD4) | 108 | 4.3% |
| MUNDRA SEA | 97 | 3.8% |
| BANGALORE ICD | 97 | 3.8% |
What Other Immunosuppressants Products Does Sandoz Private Limited Export?
Sandoz Private Limited also exports these immunosuppressants products. Each links to the detailed product page.
Geopolitical & Trade Policy Impact on Sandoz Private Limited's Mycophenolate Exports
The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Sandoz Private Limited. The escalation of conflicts in West Asia, particularly between Israel and Iran, has disrupted vital trade corridors such as the Red Sea and the Strait of Hormuz. These disruptions have led to increased shipping costs and extended transit times, impacting the timely delivery of pharmaceutical products. The Pharmaceuticals Export Promotion Council of India (Pharmexcil) has warned that prolonged disruptions could result in potential losses of up to ₹5,000 crore for the industry. (timesofindia.indiatimes.com)
Conversely, the ongoing US-China trade tensions have prompted the United States to diversify its pharmaceutical supply chain, creating opportunities for Indian exporters. Sandoz's established presence and compliance with international quality standards position it favorably to capitalize on this shift. However, the company must navigate the complexities of the European Union's Falsified Medicines Directive, which imposes stringent regulations to prevent counterfeit medicines from entering the supply chain. Adherence to these regulations is crucial for maintaining access to the lucrative EU market.
Sandoz Private Limited — Regulatory Compliance & Quality Standards
Compliance with international regulatory standards is paramount for Sandoz Private Limited. The company adheres to guidelines set forth by the U.S. Food and Drug Administration (FDA), the World Health Organization (WHO), and the European Union's Good Manufacturing Practices (EU GMP). Maintaining these certifications ensures the quality and safety of its products, facilitating access to global markets.
The evolving regulatory environment necessitates continuous investment in quality assurance and compliance. Sandoz's commitment to these standards not only mitigates the risk of regulatory actions but also enhances its reputation as a reliable supplier in the competitive pharmaceutical export market.
About Sandoz Private Limited
Sandoz Private Limited exports 25 products worth $159.4M. Beyond Mycophenolate, top products include Tacrolimus, Apixaban, Citalopram, Escitalopram, Gabapentin. View the complete Sandoz Private Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Mycophenolate — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Mycophenolate shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Sandoz Private Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 204 individual customs records matching Sandoz Private Limited exporting Mycophenolate, covering 85 formulations to 8 countries via 24 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 100+ countries, 512+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Mycophenolate Export Data from Sandoz Private Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Sandoz Private Limited's Mycophenolate exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Sandoz Private Limited
Full Company Profile →
25 products · $159.4M total trade · 15 categories
Mycophenolate Stats
Company Overview
Top Products by Sandoz Private Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Sandoz Private Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Mycophenolate. For current shipment-level data, contact TransData Nexus.